drugset / Trial / NCT06813911
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C).
Timeline
- Start
- 2025-04-30
- Primary completion
- 2028-02-03
- Completion
- 2028-02-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pelacarsen | Antisense oligonucleotide | 80 mg | Subcutaneous |
| Comparator | Inclisiran | Small interfering RNA (siRNA) | — | — |